Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias

@article{Morgan2005MolecularlyTT,
  title={Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias},
  author={Michael A. Morgan and Christoph W. M. Reuter},
  journal={Annals of Hematology},
  year={2005},
  volume={85},
  pages={139-163}
}
Although there has been significant progress in acute myeloid leukemia (AML) treatment in younger adults during the last decade, standard induction therapy still fails to induce remission in up to 40% of AML patients. Additionally, relapses are common in 50–70% of patients who achieve a complete remission, and only 20–30% of patients enjoy long-term disease-free survival. The natural history of myelodysplastic syndrome (MDS) is variable, with about half of the patients dying from cytopenic… CONTINUE READING
11 Citations
214 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 214 references

Results of a Phase I/II study of the combination of 5-aza-2-deoxycytidine (DAC) and Valproic Acid (VPA) in patients (pts) with Leukemia

  • G Garcia-Manero, H Kantarjian, +13 authors JP Issa
  • Blood
  • 2004
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…